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Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that
presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In
Parkinson’s disease patients, CBD is able to attenuate the psychotic symptoms induced
by L-DOPA and to improve quality of life. Repeated administration of reserpine in rodents
induces motor impairments that are accompanied by cognitive deficits, and has been
applied to model both tardive dyskinesia and Parkinson’s disease. The present study
investigated whether CBD administration would attenuate reserpine-induced motor
and cognitive impairments in rats. Male Wistar rats received four injections of CBD
(0.5 or 5 mg/kg) or vehicle (days 2–5). On days 3 and 5, animals received also
one injection of 1 mg/kg reserpine or vehicle. Locomotor activity, vacuous chewing
movements, and catalepsy were assessed from day 1 to day 7. On days 8 and 9,
we evaluated animals’ performance on the plus-maze discriminative avoidance task,
for learning/memory assessment. CBD (0.5 and 5 mg/kg) attenuated the increase in
catalepsy behavior and in oral movements – but not the decrease in locomotion –
induced by reserpine. CBD (0.5 mg/kg) also ameliorated the reserpine-induced memory
deficit in the discriminative avoidance task. Our data show that CBD is able to attenuate
motor and cognitive impairments induced by reserpine, suggesting the use of this
compound in the pharmacotherapy of Parkinson’s disease and tardive dyskinesia.
Keywords: reserpine, cannabidiol, Parkinson’s disease, tardive dyskinesia, schizophrenia, rat
INTRODUCTION
Alterations in the dopaminergic nigrostriatal pathway are linked to important movement
disorders, such as Parkinson’s disease and tardive dyskinesia (Mehler-Wex et al., 2006). Parkinson’s
disease affects 1–2% of individuals older than 60 years (Van Den Eeden et al., 2003). It comprises
motor impairments (e.g., hypokinesia, tremors, muscle rigidity) and non-motor symptoms (e.g.,
anxiety, deficits in cognitive function; Klockgether, 2004). The pharmacotherapy of Parkinson’s
disease is mainly symptomatic and is associated with important side effects, such as dyskinesia,
Frontiers in Pharmacology | www.frontiersin.org 1 September 2016 | Volume 7 | Article 343
fphar-07-00343 September 28, 2016 Time: 18:4 # 2
Peres et al. Cannabidiol Prevents Motor and Cognitive Impairments
psychosis, and abuse of anti-parkinsonian drugs (Cenci et al.,
2011). Tardive dyskinesia is an extrapyramidal side effect seen
in 10–30% of patients chronically treated with antipsychotics
(Correll and Schenk, 2008). This prevalence increases with
aging (Goldberg, 2003). Patients with tardive dyskinesia display
mainly orofacial-buccal-lingual stereotypic movements, and this
is irreversible in the majority of patients (Lerner et al., 2015).
Therefore, advances in the pharmacotherapy of both Parkinson’s
disease and tardive dyskinesia are in need. In rodents, repeated
administration of reserpine induces motor impairments (e.g.,
catalepsy, increased oral movements, and decreased locomotor
activity) accompanied by cognitive deficits. As a result, this
monoamine depleting agent is used to model both Parkinson’s
disease and tardive dyskinesia (Abilio et al., 2002, 2004; Silva et al.,
2002; Carvalho et al., 2006; Fernandes et al., 2012; Santos et al.,
2013; Leao et al., 2015; Nade et al., 2015; de Freitas et al., 2016).
Cannabidiol (CBD) is one of over 60 compounds of Cannabis
sativa, being the most abundant after 19-tetrahydrocannabinol
(19-THC). CBD antagonizes cannabinoid CB1/CB2 receptors
agonists and inhibits the reuptake of anandamide, the main
endogenous cannabinoid. CBD is also an agonist of the serotonin
receptor 5-HT1A and of the vanilloid receptors TRPV1 and
TRPV2 (Izzo et al., 2009). CBD presents antipsychotic, anxiolytic,
anti-inflammatory, and neuroprotective effects (Zuardi, 2008). In
Parkinson’s disease patients, treatment with CBD attenuates the
psychotic symptoms induced by L-DOPA (Zuardi et al., 2009)
and improves non-motor symptoms and quality of life (Chagas
et al., 2014a,b). Moreover, a pre-clinical study revealed that CBD
administration prevents the catalepsy induced by haloperidol,
WIN 55,212-2, and L-nitro-N-arginine (Gomes et al., 2013).
Nonetheless, so far no study has investigated CBD’s effects on the
reserpine model.
The aim of this study was to investigate whether treatment
with CBD would attenuate the motor and cognitive impairments
induced by repeated administration of reserpine in rats.
MATERIALS AND METHODS
Animals
Three-month-old male Wistar rats (WR; n = 40), from our
own colony, were used. Animals were maintained in groups of
five in Plexiglas cages (41 × 34 × 16.5 cm) under controlled
environmental conditions (22–23◦C, light/dark cycle: lights on
6:30–18:30) with free access to food and water. The procedures
of the present study were approved by the Ethics Committee of
Federal University of São Paulo (N◦ 7798280515), and followed
the guidelines of the Committee on Care and Use of Laboratory
Animal Resources, National Research Council, USA, and of the
Brazilian law for the use of animals in research (Law Number
11.794). All animals were drug-naïve.
Drugs
Cannabidiol (THC-Pharm, Frankfurt, Germany) was prepared
daily, diluted in saline and 1% tween-80. Reserpine (Sigma
Chemical Co., St. Louis, MO, USA) was diluted in 0.5% glacial
acetic acid and distilled water. CBD and its vehicle were
administered intraperitoneally. Reserpine and its vehicle were
administered subcutaneously. Solutions were given in a volume
of 1 ml/kg of body weight.
Behavioral Analysis
Locomotor Activity
Locomotor activity (Abilio et al., 2003b) was assessed in a circular
open-field arena (97 cm in diameter and 32.5 cm high, with an
open top and a floor divided into 19 similar quadrants). The
animals were individually placed on the apparatus. Number of
floor squares entered was quantified by an automated activity
monitoring system (AnyMaze, Stoelting, USA) during 5 min.
Catalepsy
Catalepsy behavior (Fernandes et al., 2012) was assessed by
placing each animal’s forepaws on a horizontal bar elevated 9 cm
from the bench surface. The amount of time the animal remained
in the same imposed position was scored live until a maximum
of 180 s. Three trials were carried out for each animal in each
observational day. The results were analyzed considering the
mean value of the three trials.
Vacuous Chewing Movements
Vacuous chewing movements (Abilio et al., 2004) were
assessed by placing the animals in individual wired cages
(40 × 40.5 × 20 cm). Mirrors were placed behind the back and
under the bottom to allow behavioral quantification when the
animal faced away from the observer. The amount of vacuous
chewing movements (mouth openings in the vertical plane not
directed toward physical material) was quantified live during
10 min.
Plus-Maze Discriminative Avoidance Task
Plus-maze discriminative avoidance task allows the simultaneous
evaluation of learning, memory, anxiety, and locomotor activity
(Fernandes et al., 2012). The apparatus employed was a
modified elevated plus-maze, comprising two enclosed arms
(50 × 15 × 40 cm) opposite to two open arms (50 × 15 cm).
A lamp and a speaker were placed over one of the enclosed arms
(aversive arm). In the training session, each animal was placed
in the center of the apparatus. Every time it entered the aversive
enclosed arm, the animal was submitted to 100 W light and 80 dB
noise (aversive stimuli) until it left the arm. Twenty-four hours
later, the animals were submitted to the test session. Each animal
was placed in the center of the apparatus without being submitted
to aversive stimuli (the lamp and the speaker were still placed over
the aversive arm, but were not turned on). Both sessions lasted
10 min.
Distance traveled in the apparatus (used for evaluation of
motor activity) and time spent in each arm (aversive, non-
aversive, and open arms) were quantified in training and
test sessions at 1-minute intervals by an automated activity
monitoring system (AnyMaze, Stoelting, USA). Percent time in
the open arms (total time spent in open arms/total time spent
in open and enclosed arms) in training session was calculated to
evaluate anxiety. Percentage of time in the aversive arm (time
spent in aversive enclosed arm/time spent in both enclosed
Frontiers in Pharmacology | www.frontiersin.org 2 September 2016 | Volume 7 | Article 343
fphar-07-00343 September 28, 2016 Time: 18:4 # 3
Peres et al. Cannabidiol Prevents Motor and Cognitive Impairments
arms), assessed minute by minute across the training session,
was employed to assess learning. Total time spent in the aversive
vs. non-aversive arms in the training session was also used
to evaluate learning. Total time spent in the aversive vs. non-
aversive arms in the test session was used to evaluate memory.
The observers were blind to the animals’ experimental
condition.
Experimental Design
The animals received four injections of CBD (0.5 or 5 mg/kg) or
vehicle on days 2–5, and two injections of reserpine (1 mg/kg) or
vehicle on days 3 and 5. The drug regimen for the administration
of reserpine was based on previous reports that show reserpine-
induced oral dyskinesia, catalepsy, and memory impairments
(Silva et al., 2002; Abilio et al., 2003a, 2004). The doses of CBD
were chosen based on a previous work from our group showing
beneficial effects of CBD at this same range of doses (Levin et al.,
2012). Locomotor activity, vacuous chewing movements, and
catalepsy behavior were assessed on days 1–7. On days 8 and 9,
animals were submitted to the training and test sessions of the
discriminative avoidance task, respectively (Figure 1).
The experimental groups were: vehicle-vehicle (control
group), vehicle-reserpine, CBD 0.5-reserpine, and CBD 5-
reserpine (n= 10/group).
Statistical Analysis
Data from catalepsy, vacuous chewing movements, locomotor
activity and percentage of time spent in the open arms in
the training session of the discriminative avoidance task were
analyzed by one-way ANOVA, followed by Bonferroni’s post hoc.
Comparison between total time spent in the aversive- and
non-aversive enclosed arms on the training and test sessions of
discriminative avoidance task was analyzed by paired-samples
t-test.
Data from the percent time spent in the aversive enclosed
arm at 1-minute intervals throughout the training session were
analyzed by repeated measures ANOVA, with time within session
as the within-subject factor.
RESULTS
Locomotor Activity
One-way ANOVA revealed effect of treatment on days 5 (after
injection) [F(3,39) = 3.694; p < 0.05], 6 [F(3,39) = 6.030;
p < 0.005] and 7 [F(3,39) = 6.627; p < 0.005]. Bonferroni’s
test showed that on day 5 (after injection), the group vehicle-
reserpine displayed decreased locomotion when compared to
the control group (vehicle-vehicle). On day 6, all the reserpine-
treated groups displayed diminished locomotor activity when
compared to control. On day 7, vehicle-reserpine and CBD 0.5-
reserpine groups, but not CBD 5-reserpine, displayed decreased
locomotor activity when compared to control. In all comparisons,
CBD-treated groups did not differ from vehicle-reserpine group.
Treatment with CBD was not able to attenuate the decrease in
locomotion induced by reserpine (Table 1).
Catalepsy
One-way ANOVA revealed effect of treatment on day 7
[F(3,39) = 3.510; p < 0.05]. Bonferroni’s test showed that
vehicle-reserpine group displayed increased catalepsy behavior
when compared to control group. CBD-treated groups did not
differ from control or from vehicle-reserpine group. Treatment
with CBD attenuated the reserpine-induced increase in catalepsy
(Figure 2).
Vacuous Chewing Movements
One-way ANOVA revealed effect of treatment on days 5 (before
injection) [F(3,39) = 3.069; p < 0.05], 6 [F(3,39) = 3.332;
p < 0.05], and 7 [F(3,39) = 4.661; p < 0.05]. Bonferroni’s
test showed that vehicle-reserpine group displayed increased
vacuous chewing movements when compared to control group.
CBD-treated groups did not differ from control or from vehicle-
reserpine group. Treatment with CBD attenuated the reserpine-
induced increase in oral movements (Figure 3).
Discriminative Avoidance Task
For the percent time spent in the aversive arm in the training
session, repeated one-way ANOVA revealed effect of time
[F(9,315) = 7.351; p < 0.001], but not of treatment or of
an interaction between factors. All groups showed a decrease
in the time spent in the aversive arm throughout the session
(Figure 4A). In addition, paired t-test showed that all groups
spent more time in the non-aversive enclosed arm than in the
aversive enclosed arm: vehicle-vehicle [t(9)=−7.667; p< 0.001],
vehicle-reserpine [t(9)=−13.900; p< 0.001], CBD 0.5-reserpine
[t(9)=−8.984; p< 0.001], and CBD 5-reserpine [t(9)=−8.321;
p < 0.001] (Figure 4B). All groups showed adequate learning of
the task.
In the test session, paired t-test showed that the time spent
in the aversive enclosed arm is lower than the time spent in the
non-aversive enclosed arms for vehicle-vehicle [t(9) = −2.366;
p < 0.05] and CBD 0.5-reserpine [t(9) = −2.289; p < 0.05]
groups, but not for the vehicle-reserpine and CBD 5-reserpine
groups. Treatment with reserpine impaired animals’ retrieval of
the discriminative avoidance task, and this effect was prevented
by treatment with CBD 0.5, but not with CBD 5 (Figure 4C).
Moreover, in the training session there was no effect of
treatment on the percent time spent in the open arms, but
treatment affected the distance traveled [F(3,39) = 6.362;
p < 0.001] (Table 2). All groups treated with reserpine displayed
diminished locomotor activity when compared to control group,
and treatment with CBD and/or reserpine did not alter animals’
anxiety levels.
DISCUSSION
The present study showed that CBD administration ameliorates
motor and cognitive impairments promoted by reserpine,
an animal model for both Parkinson’s disease and tardive
dyskinesia. CBD attenuated the reserpine-induced catalepsy
behavior, increase in oral movements and memory deficit, but not
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FIGURE 1 | Experimental design. The animals received four injections of CBD (0.5 or 5 mg/kg) or vehicle (saline + 1% tween-80) on days 2–5, and two injections
of reserpine (1 mg/kg) or vehicle (0.5% glacial acetic acid + distilled water) on days 3 and 5. Locomotor activity, vacuous chewing movements, and catalepsy
behavior were assessed on days 1–7. On days 8 and 9, animals were submitted to the training and test sessions of the discriminative avoidance task, respectively.
CBD, cannabidiol; RES, reserpine; VEH, vehicle. n = 10/group.
TABLE 1 | Squares crossed in the open field arena by Wistar rats
(n = 10/group) treated with CBD (0.5 or 5 mg/kg) or vehicle (VEH –
saline + 1% tween-80) in addition to reserpine (RES – 1 mg/kg) or vehicle
(VEH – 0.5% glacial acetic acid + distilled water).
VEH-VEH VEH-RES CBD 0.5-RES CBD 5-RES
Day 1 82.9 ± 5.9 93.0 ± 8.9 98.2 ± 5.0 108.0 ± 7.0
Day 2 78.7 ± 9.2 85.5 ± 12.8 78.3 ± 7.8 89.9 ± 7.6
Day 3 72.6 ± 8.9 63.9 ± 14.2 62.1 ± 10.9 64.2 ± 10.5
Day 4 44.7 ± 10.8 29.2 ± 9.7 16.8 ± 4.8 23.0 ± 4.4
Day 5 Before 36.4 ± 10.3 31.5 ± 9.5 15.5 ± 4.2 28.1 ± 12,3
Day 5 After 31.8 ± 6.0 5.3 ± 1.9∗ 14.8 ± 6.5 13.0 ± 6.8
Day 6 40.4 ± 10.5 12.9 ± 5.2∗ 10.7 ± 3.2∗ 7.4 ± 2.2∗
Day 7 46.4 ± 9.0 13.1 ± 2.5∗ 16.5 ± 4.5∗ 24.0 ± 5.3
∗p < 0.05 when compared to VEH-VEH group. One-way ANOVA followed by
Bonferroni’s test. Data expressed as mean ± SEM.
the decrease in locomotor activity. In addition, treatment with
CBD and/or reserpine did not modify animals’ anxiety levels.
Reserpine irreversibly blocks the vesicular monoamine
transporters 1 and 2 (VMAT-1 and VMAT-2), interfering with the
storage of monoamines in synaptic vesicles. As a consequence,
it increases the intracellular levels of monoamines and induces
monoamine depletion in nerve terminals. The increase in
intracellular levels of monoamines enhances their metabolism
by the enzyme monoamine oxidase (MAO), increasing oxidative
stress (for a review, see Leao et al., 2015). Here, reserpine
administration augmented rats’ oral movements – a model for
tardive dyskinesia (Waddington et al., 1983; Neisewander et al.,
1994). Reserpine also increased rats’ catalepsy behavior and
decreased their locomotor activity – motor impairments used to
model symptoms of Parkinson’s disease (Leao et al., 2015). These
effects are in accordance with previous reports (Abilio et al., 2002,
2004; Silva et al., 2002; Carvalho et al., 2006; Fernandes et al.,
2012; Santos et al., 2013; Leao et al., 2015; Nade et al., 2015; de
Freitas et al., 2016).
It is noteworthy that some schizophrenia patients display
both parkinsonism-like symptoms and tardive dyskinesia (Fann
and Lake, 1974; Richardson and Craig, 1982; Bitton and
Melamed, 1984; Saito et al., 1986). This coexistence indicates that
these motor disturbances share a common pathophysiological
mechanism. Indeed, oxidative damage – a widely described
outcome of reserpine administration (Abilio et al., 2002, 2003a;
Burger et al., 2003; Fernandes et al., 2012; Nade et al., 2013;
Leao et al., 2015) – is linked to both Parkinson’s disease
and tardive dyskinesia. Augmented oxidative stress indices are
seen in schizophrenia patients with tardive dyskinesia, when
compared to those without it (Zhang et al., 2007). Regarding
Parkinson’s disease, several studies show increased oxidative
stress parameters in peripheral blood, cerebrospinal fluid, and
brains of patients (Dexter et al., 1994; Serra et al., 2001; Boll
et al., 2008; Sharma et al., 2008; Mythri et al., 2011; de Farias
et al., 2016). Also, the genetic defects associated with Parkinson’s
disease are directly or indirectly related to oxidative stress (Gao
and Hong, 2011).
Interestingly, reserpine effects on locomotor activity and
vacuous chewing movements were not seen until day 5 (second
injection of reserpine) and the effect on catalepsy was only
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FIGURE 2 | Catalepsy time of Wistar rats (n = 10/group) treated with CBD (0.5 or 5 mg/kg) or vehicle (VEH – saline + 1% tween-80) in addition to
reserpine (RES – 1 mg/kg) or vehicle (VEH – 0.5% glacial acetic acid + distilled water). ∗p < 0.05 when compared to VEH-VEH group. One-way ANOVA
followed by Bonferroni’s test. Data expressed as mean ± SEM.
FIGURE 3 | Vacuous chewing movements of Wistar rats (n = 10/group) treated with CBD (0.5 or 5 mg/kg) or vehicle (VEH – saline + 1% tween-80) in
addition to reserpine (RES – 1 mg/kg) or vehicle (VEH – 0.5% glacial acetic acid + distilled water). ∗p < 0.05 when compared to VEH-VEH group.
One-way ANOVA followed by Bonferroni’s test. Data expressed as mean ± SEM.
statistically significant on day 7 (48 h after the second injection of
reserpine). Also, the effect of reserpine on memory was observed
96 h after the second injection. The time course for the emergence
of motor abnormalities and memory impairments suggests a
non-acute progressive effect of reserpine. Therefore, this effect
fits better to the oxidative damage than to the acute monoamine
depletion induced by reserpine.
Cannabidiol (0.5 or 5 mg/kg) attenuated the increase in
catalepsy behavior and in oral dyskinesia, which is in accordance
with clinical and pre-clinical findings. In humans, CBD is able
to improve dystonia (Consroe et al., 1986; Sandyk et al., 1986).
Parkinson’s disease patients treated with CBD during 4 weeks, in
addition to their usual treatment, show a decrease in the score of
the Unified Parkinson’s Disease Rating Scale (UPDRS) that assess
motor and non-motor symptoms (Zuardi et al., 2009). In mice,
CBD acute administration prevents the increase in catalepsy
behavior induced by haloperidol (an antagonist of dopamine
D2 receptors), WIN 55,212-2 (a CB1/CB2 agonist), and L-nitro-
N-arginine (a non-selective inhibitor of nitric oxide synthase),
therefore showing CBD’s potential on inhibiting the catalepsy
induced by different mechanisms of action (Gomes et al., 2013).
Conversely, CBD was not able to attenuate – only to
delay – the reserpine-induced decrease in locomotor activity,
suggesting it is effective in inhibiting the emergence of some
but not all the parkinsonism-like motor abnormalities. This
outcome also indicates that the pathophysiological mechanisms
related to the reserpine effect on locomotion are distinct
from those on catalepsy and oral movements. In fact, while
catalepsy behavior and oral movements in rats are linked to the
dopaminergic nigrostriatal pathway (Morelli et al., 1981; Carey,
1983; Neisewander et al., 1996), locomotor activity is associated
with the mesolimbic pathway (Kelly and Iversen, 1976; Carey,
1983; Neisewander et al., 1996). Interestingly, when administered
intra-nucleus accumbens shell, CBD presents an antipsychotic
action against amphetamine-induced locomotor sensitization
and deficit in prepulse inhibition of startle. These effects seem
to be mediated by different striatal molecular mechanisms than
those of the known antipsychotic drugs. The authors suggest that
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FIGURE 4 | Performance in the discriminative avoidance task of Wistar rats (n = 10/group) treated with CBD (0.5 or 5 mg/kg) or vehicle (VEH –
saline + 1% tween-80) in addition to reserpine (RES – 1 mg/kg) or vehicle (VEH – 0.5% glacial acetic acid + distilled water). Percentage of time spent in
the aversive arm in the training session at 1-minute intervals (A). Time spent in aversive and non-aversive enclosed arms in the training (B) and test (C) sessions.
∗p < 0.05 when compared to the aversive arm. Repeated measures ANOVA (A) and paired-samples t-test (B,C). Data expressed as mean ± SEM.
this differential molecular signaling might be related to CBD’s
absence of adverse effects typically associated with antipsychotics
(Renard et al., 2016). In regard to motor side effects, this rationale
suits the beneficial effects of CBD against the motor impairments
induced by reserpine.
Reserpine did not alter anxiety-like behavior or learning,
but impaired memory in the discriminative avoidance task.
These results are in accordance with previous reports using rats
and mice (Silva et al., 2002; Carvalho et al., 2006; Fernandes
et al., 2008). Cognitive impairments are an important feature
of Parkinson’s disease and are associated with poorer quality
of life (Lawson et al., 2016). Regarding tardive dyskinesia,
schizophrenia patients with this motor abnormality display
more severe cognitive impairment (Waddington and Youssef,
1996; Wu et al., 2013, 2014; Fervaha et al., 2015). Our results
demonstrate that CBD is able to attenuate the reserpine-induced
memory deficit without modifying animals’ locomotor activity
or anxiety-like behavior. Although no study has investigated
the effects of CBD on the reserpine model, our data are
in agreement with reports showing beneficial effects of CBD
on cognitive impairments in animal models of schizophrenia
(Levin et al., 2012), cerebral malaria (Campos et al., 2015),
pneumococcal meningitis (Barichello et al., 2012), hepatic
encephalopathy (Magen et al., 2009), and neurodegenerative
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TABLE 2 | Distance traveled (m) and percentage of time spent in the open
arms in the training session of the plus-maze discriminative avoidance
task by Wistar rats (n = 10/group) treated with CBD (0.5 or 5 mg/kg) or
vehicle (VEH – saline + 1% tween-80) in addition to reserpine (RES –
1 mg/kg) or vehicle (VEH – 0.5% glacial acetic acid + distilled water).
Distance traveled (m) % Time spent in open arms
VEH-VEH 25.5 ± 4.9 14.4 ± 3.4
VEH-RES 12.2 ± 1.8∗ 5.9 ± 1.7
CBD 0.5-RES 12.4 ± 1.1∗ 9.4 ± 4.3
CBD 5-RES 10.6 ± 1.2∗ 8.3 ± 3.1
∗p < 0.05 when compared to VEH-VEH group. One-way ANOVA followed by
Bonferroni’s test. Data expressed as mean ± SEM.
disorders (Fagherazzi et al., 2012). Considering the role of
the mesolimbic pathway on cognitive processes (Pezze and
Feldon, 2004; Rinaldi et al., 2012; Braun et al., 2016), it
is worth mentioning that intra-accumbal administration of
CBD modulates an emotional memory task (Norris et al.,
2016).
It is worth mentioning that only the 0.5 mg/kg dose of
CBD had a beneficial effect on memory. This is in agreement
with previous data showing an inverted U-shaped dose-response
curve for CBD on behavioral assessments. The CBD inverted
U-shaped curve is seen in pre-clinical tests of anxiety and
prepulse inhibition of startle (Guimaraes et al., 1990; Levin et al.,
2014; Nazario et al., 2015). In addition, studies from our group
show that only the lowest dose of CBD (1 mg/kg) is effective
against the social interaction and contextual fear conditioning
deficits in an animal model of schizophrenia (Levin et al., 2012;
Almeida et al., 2013). Inverted U-shaped dose-response curves
are also seen for other cannabinoid drugs, such as WIN 55,212-2
(Almeida et al., 2014; Levin et al., 2014) and 19-THC (El-Alfy
et al., 2010). This U-shaped pattern is probably the result of
the modulatory role of the endocannabinoid system on different
neurotransmission targets.
The mechanisms whereby CBD exerts these beneficial effects
are beyond the scope of this work. However, as mentioned,
oxidative stress is linked to the reserpine effects, to Parkinson’s
disease and tardive dyskinesia. Previous data from our group
show that the effects of reserpine are potentiated by a pro-oxidant
compound (Calvente et al., 2002) and attenuated by the free
radical scavengers vitamin C, vitamin E, and melatonin (Abilio
et al., 2002, 2003a; Faria et al., 2005). In accordance, CBD has
been described to present antioxidant, anti-inflammatory, and
neuroprotective actions. The antioxidant effects of CBD are seen
in rat models of binge alcohol consumption (Hamelink et al.,
2005), sepsis (Cassol-Jr et al., 2010), mania (Valvassori et al.,
2011), epilepsy (Hosseinzadeh et al., 2016), and Huntington
(Sagredo et al., 2011). In the 6-hydroxydopamine rat model for
Parkinson’s disease, treatment with CBD for 2 weeks prevents
the neurodegeneration produced by the unilateral injection of
the toxin into the medial forebrain bundle (Lastres-Becker
et al., 2005). CBD administration in this model up-regulates
the mRNA levels for the antioxidant enzyme copper-zinc
superoxide dismutase (Garcia-Arencibia et al., 2007). Although
other mechanisms cannot be disregarded, CBD’s antioxidant and
anti-inflammatory actions are possibly involved in its beneficial
effects on the reserpine model.
Aiming to diminish the amount of animals used in the
study, we did not include groups treated with CBD and vehicle.
Nonetheless, multiple studies show that CBD does not induce
catalepsy or oral dyskinesia per se, even at high doses (Zuardi
et al., 1991; Moreira and Guimaraes, 2005; Hayakawa et al., 2008;
Long et al., 2010; Gomes et al., 2013; Dos-Santos-Pereira et al.,
2016). Studies also report absence of CBD’s effect on locomotor
activity in the dose range used here (Hayakawa et al., 2008; Long
et al., 2010; Almeida et al., 2013).
In summary, we showed here that CBD can attenuate
the motor and cognitive impairments induced by reserpine.
These data suggest CBD’s application on the treatment of
tardive dyskinesia and Parkinson’s disease, conditions whose
pharmacotherapy remain unsatisfactory. Therefore, preventing
the emergence of motor symptoms would represent a major
advance in patients’ quality of life. It is worth mentioning
that CBD is also effective on treating the psychotic symptoms
of both Parkinson’s disease and schizophrenia patients (Iseger
and Bossong, 2015) without inducing the parkinsonian and
dyskinetic adverse effects associated with classical antipsychotic
drugs. Further studies are in need, but data suggest that including
CBD on the pharmacotherapy of Parkinson’s disease and tardive
dyskinesia might be beneficial to the motor and cognitive
impairments, and also to patients’ psychiatric symptoms.
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